Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nonalcoholic steatohepatitis (NASH)
Biotech
Chinese biotech's MASH drug reduces liver fat in phase 2 trial
Chipscreen Biosciences' MASH candidate reduced patients' liver fat levels, adding further momentum to drugs aimed at the condition.
Max Bayer
Mar 18, 2024 11:07am
Akero soars as liver scarring improves in longer MASH trial
Mar 4, 2024 6:30am
Boehringer links GLP-1 agonist to scarring improvements in MASH
Feb 26, 2024 6:17am
Terns bows out of MASH race, reverts back to phase 1
Jan 5, 2024 9:57am
Boehringer bets $2B in biobucks on siRNA treatments for MASH
Jan 3, 2024 6:00am
Gannex posts data on NASH asset at center of trade secret row
Jan 2, 2024 9:54am